Vivani Medical Valuation
Is U5P undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of U5P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate U5P's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate U5P's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for U5P?
Key metric: As U5P is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is U5P's PB Ratio? | |
|---|---|
| PB Ratio | 3.9x |
| Book | US$18.33m |
| Market Cap | US$71.28m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does U5P's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.5x | ||
PUS PULSION Medical Systems | 6.5x | n/a | €134.4m |
AAQ1 aap Implantate | 1.5x | n/a | €22.2m |
NN6 NanoRepro | 0.5x | n/a | €20.1m |
SBS Stratec | 1.5x | 25.4% | €339.8m |
U5P Vivani Medical | 3.9x | -10.3% | €71.3m |
Price-To-Book vs Peers: U5P is expensive based on its Price-To-Book Ratio (3.9x) compared to the peer average (2.5x).
Price to Book Ratio vs Industry
How does U5P's PB Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Book vs Industry: U5P is expensive based on its Price-To-Book Ratio (3.9x) compared to the European Medical Equipment industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is U5P's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate U5P's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.12
7D
-3.1%
1Y
5.2%
Shandong Weigao Group Medical Polymer
HK$20.6b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-13.2%
1Y
-37.9%
LNA Santé
€243.4m
Engages in the management and operation of health establishments.
2N3
€23.45
7D
-5.6%
1Y
16.1%